IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.205
+0.029 (2.49%)
Apr 1, 2025, 10:21 AM EDT - Market open
IceCure Medical Revenue
In the year 2024, IceCure Medical had annual revenue of $3.29M with 1.92% growth. IceCure Medical had revenue of $875.00K in the quarter ending December 31, 2024, a decrease of -30.28%.
Revenue (ttm)
$3.29M
Revenue Growth
+1.92%
P/S Ratio
18.18
Revenue / Employee
$42,740
Employees
77
Market Cap
68.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | 3.87M | -1.87M | -32.61% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
ICCM News
- 4 days ago - IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 days ago - IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America - PRNewsWire
- 8 days ago - IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate - PRNewsWire
- 11 days ago - IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025 - PRNewsWire
- 12 days ago - IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer - PRNewsWire
- 14 days ago - IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference - PRNewsWire
- 15 days ago - IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology - PRNewsWire
- 22 days ago - Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery - PRNewsWire